Literature DB >> 11677376

Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake.

C D Griffiths1, T O Morgan, L M Delbridge.   

Abstract

BACKGROUND: To prevent the action of angiotensin II by blockade with either an angiotensin converting enzyme inhibitor (ACE I) or an angiotensin receptor antagonist (ARA) is difficult due to the physiological compensations. Combined therapy with both drugs may enable complete blockade, and in rats in high doses this has produced a syndrome that results in death.
OBJECTIVE: To determine the effect of combined blockade using losartan (10 mg/kg per day) and perindopril (6 mg/kg per day) on blood pressure, cardiac growth, renal function and behaviour, and to determine how this is influenced by different salt intakes in normotensive Sprague Dawley rats.
METHODS: Rats were fed an 0.2 or 4% NaCl diet and received the above drugs intraperitoneally. Blood pressure was measured by telemetry. Cardiac weight was measured after 10 days of therapy. Renal function was assessed by plasma creatinine and electrolytes, plasma renin and angiotensinogen concentrations were measured.
RESULTS: On 0.2% NaCl intake, combined blockade lowered blood pressure progressively; at day 7, rats on 0.2% NaCl developed a syndrome of listlessness and failure to eat which led to loss of weight and death. Cardiac size was dramatically reduced. Plasma creatinine was elevated to 50% above normal. There was a polyuria. The syndrome was reversed by adding NaCl to the drinking water or prevented in rats on a 4% NaCl intake. In rats on 0.2% NaCl plasma renin rose dramatically with medication and angiotensinogen became depleted. Haematocrit in all groups of rats did not differ.
CONCLUSION: Combined blockade of the renin-angiotensin system can cause death in rats on a reduced NaCl intake. This was prevented by a high salt intake. The syndrome may result from depletion of angiotensinogen and the failure to synthesize sufficient angiotensin II that may be critical for normal cardiac growth and function and critical for survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677376     DOI: 10.1097/00004872-200111000-00021

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

1.  Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney.

Authors:  Klaus Höcherl; Corina Hensel; Bettina Ulbricht; Bernhard K Krämer
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 2.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

Review 3.  Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

Review 4.  Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.